Collegium Pharmaceutical (COLL) Non-Current Debt (2014 - 2026)

Collegium Pharmaceutical has reported Non-Current Debt for 13 years, with the latest figure at $797.8 million in Q2 2026.

• On a quarterly basis, Non-Current Debt rose 53.24% year-over-year to $797.8 million in Q2 2026; TTM through Jun 2026 was $797.8 million, a 53.24% increase from a year earlier, with the FY2025 full-year figure at $542.1 million, down 1.57% from the prior year.
• Non-Current Debt was $797.8 million for Q2 2026 at Collegium Pharmaceutical, up from $531.7 million in the prior quarter.
• The five-year high for Non-Current Debt was $797.8 million in Q2 2026, with the low at $132.8 million in Q2 2024.
• Average Non-Current Debt over 5 years is $436.9 million, with a median of $495.2 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2024: Non-Current Debt soared 544.73% in 2022, then sank 57.13% in 2024.
• Over 5 years, Non-Current Debt stood at $397.6 million in 2022, then sank by 44.23% to $221.7 million in 2023, then surged by 148.4% to $550.7 million in 2024, then slipped by 1.57% to $542.1 million in 2025, then surged by 47.17% to $797.8 million in 2026.
• The last three Non-Current Debt figures came in at $797.8 million (Q2 2026), $531.7 million (Q1 2026), and $542.1 million (Q4 2025), per Business Quant data.